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Chronic pain remains a significant clinical problem despite substantial advances in our understanding of how
persistent nociceptor stimulation drives plasticity in the CNS. A major theme that has emerged in this area of work
is the strong similarity between plasticity involved in learning and memory in CNS regions such as cortex and
hippocampus with mechanisms underlying chronic pain development and maintenance in the spinal dorsal horn
and other CNS areas such as anterior cingulate cortex (ACC). We, and others have recently implicated an atypical
PKC (aPKC), called PKMζ, in the maintenance of pain plasticity based on biochemical assays and the use of a
peptide pseudosubstrate inhibitor called ZIP. These studies indicate remarkable parallels between the potential role
of PKMζ as a key molecule for the maintenance of long-term memory and long-term potentiation (LTP) and the
maintenance of a chronic pain state. On the other hand, very recent studies have disputed the specificity of ZIP
and called into question the role of PKMζ as a memory maintenance molecule. Here we critically review the
evidence that PKMζ might represent a new target for the reversal of certain chronic pain states. Furthermore, we
consider whether ZIP might have other aPKC or even non-aPKC targets and the significance of such off-target
effects for evaluating maintenance mechanisms of chronic pain. We conclude that, current controversies aside,
utilization of ZIP as a tool to interrogate maintenance mechanisms of chronic pain and further investigations into
the potential role of PKMζ, and other aPKCs, in pain plasticity are likely to lead to further insights with the potential
to unravel the enigma that is the disease of chronic pain.Chronic pain as a disease of CNS plasticity
While plasticity in the CNS is often associated with
beneficial processes such as learning and memory, the
past decades have brought extensive evidence that dis-
ease states, such as addiction and chronic pain also
involve CNS plasticity. One of the most commonly
studied neurophysiological substrates of this plasticity
is long-term potentiation (LTP, [1]). LTP is thought to
underlie some forms of learning and memory and,
likewise, has been implicated in aspects of addictive
behaviors [2] and in nociceptive plasticity [3]. LTP can
be divided into an early and late phase with the late
phase commencing at least 3 hours after the LTP ini-
tiating event. Importantly, these early and late phases
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distribution, and reproduction in any medium[4]. Early-LTP involves the phosphorylation of a variety
of ionotropic glutamate receptors mediated by kinases
such as classical PKC, PKA and calcium/calmodulin-
activated protein kinase II α (CaMKIIα, [5]). For early-
LTP to consolidate into late-LTP, these same kinases
must be engaged and translation of proteins, mediated
largely via the mammalian target of rapamycin (mTOR)
pathway, must occur. Once late-LTP has consolidated,
inhibition of these same mechanisms is no longer able
to reverse established late-LTP [6]. Original theories on
the maintenance mechanisms of late-LTP suggested that
a persistently active kinase might maintain late-LTP [7].
This idea was eventually supported by evidence that
an atypical PKC, PKMζ, that lacks a regulatory region
and is therefore, at least after PDK1 phosphorylation,
autonomously active, represents the molecular engine
for the maintenance of late-LTP and long-term mem-
ory [6,8-12].
Some of the first work implicating CNS plasticity in
pain amplification came from the description of “central
sensitization” by Clifford Woolf in the early 1980s [13].tral Ltd. This is an Open Access article distributed under the terms of the
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description of LTP [14], pain neuroscientists have come
to recognize the important role that LTP, especially in
the spinal dorsal horn, might play in pain plasticity
[3,15,16]. Along with this neurophysiological evidence
have come a variety of pharmacological studies implicat-
ing the same kinases that are involved in early-LTP in
spinal pain plasticity. This topic has been extensively
reviewed by others, including the myriad similarities and
a few important differences [3,15,16]. Similarly, evidence
has emerged that pain plasticity leading to chronic
pain occurs in other CNS regions that are critical for
the processing of nociceptive inputs including, but not
limited to, the central nucleus of the amygdala [17,18]
and the anterior cingulate cortex (ACC, [19-22]). Hence, it
is now clear that the development of a long-lasting pain
state involves plasticity in the CNS [23,24]. Moreover, it is
also evident that this plasticity, once established, can lead
to the transition to a chronic pain state that is resistant
to molecular interventions that can be utilized to pro-
vide relief of an acute pain state [25-28].
A key question then is how is this chronic pain state
maintained and does inhibition of this maintenance
mechanism lead to a resolution of the chronic pain state.
Herein we will review the evidence that a pseudosubstrate
inhibitor of PKMζ, called ZIP, is able to reverse, over
differing time courses, a variety of chronic pain states
when infused into specific CNS locations [28-33]. These
findings yield important insights into how a chronic pain
state is maintained and shed light on how the presence
of ongoing afferent discharge may differentially regulate
plasticity in the CNS. They also suggest that PKMζ may
be a key molecular mechanism for pain plasticity in the
CNS [31]. However, recent studies have raised serious
questions about the specific role of PKMζ in learning
and memory and late-LTP maintenance [34,35]. We
will argue that careful consideration of these findings
opens up a variety of opportunities to gain a better
understanding of the mechanism of action of ZIP, the
role of aPKC isoforms in CNS plasticity and potential
differences between mechanisms governing amplification
of pain via CNS plasticity and learning and memory.
The atypical PKC family, PKCζ, PKCλ and PKMζ
PKC protein kinases are grouped into three major sub-
families: classical PKC, novel PKC and aPKC. There are
three major aPKC isozymes in vertebrates: PKCζ, PKCλ
(PKCι in human) and PKMζ [36,37]. PKCλ is derived
from the Prkcl gene while PKCζ and PKMζ are derived
from the Prkcz gene. PKCζ and PKCλ show a high de-
gree of amino acid sequence identity (~72% amino acid
identity overall and ~86% identity between the kinase
domain). PKCζ and PKMζ mRNAs originate from the
same gene but they have different mRNA structuresincluding an alternative translational start site. All
PKCs, except for PKMζ, share the same structural
organization – an N-terminal regulatory domain controls
the catalytic activation of a C-terminal kinase domain.
The mature mRNAs for PKCζ and PKMζ are identical
throughout the coding sequence for the catalytic region
of the kinase and the 3’ untranslated region but have
unique 5’ sequences [38]. PKMζ lacks the regulatory
region (summarized in Figure 1A).
Classical PKCs are regulated by intracellular Ca2+ and
diacylglycerol (DAG) binding at the N-terminal regula-
tory domain. Novel PKCs are insensitive to intracellular
Ca2+ but are regulated by DAG. aPKCs, on the other
hand, do not respond to either Ca2+ or DAG but are
regulated by protein-protein interactions and potentially
membrane lipid composition. All PKCs, except for PKMζ
[38], contain a pseudosubstrate motif in the N-terminal
regulatory region – a sequence of amino acids that
share identity with PKC substrates, but lacking the
phosphoacceptor residue (Figure 1A). This sequence
occupies the substrate-binding site in the C-terminal
kinase domain and keeps the kinase inactive. Activation
of PKCs displaces the pseudosubstrate region and allows
substrate binding.
The mechanism of aPKC activation is not entirely
clear from a biochemical standpoint. The maturation of
newly synthesized PKC requires interaction with HSP90
and a series of priming phosphorylations [40,41]. PDK1
constitutively phosphorylates the “activation loop” of
PKCs after synthesis. A second phosphorylation in the
“turn motif” of PKC results from autophosphorylation
or from phosphorylation by mammalian target of
rapamycin complex 2 (mTORC2). A third priming
phosphorylation occurs on the “hydrophobic motif”.
aPKCs require the activation loop phosphorylation and
are regulated downstream of PI3K and PDK1 activity
(Figure 1A) [40]. It is interesting to note that classical
PKC activation does not require sustained activation
loop phosphorylation for activity [42-44]. In fact, this
phosphorylation is downregulated in a mature kinase.
aPKCs are also phosphorylated in the turn motif [45].
However, the hydrophobic motif in aPKCs contains a
glutamic acid instead of the phospho-acceptor residue
(Figure 1A). The significance of this residue or the
requirement of HSP90 binding for aPKC remains un-
clear. The unique structure of PKMζ lacking the
regulatory domain and the pseudosubstrate sequence
is proposed to impart the kinase with constitutive ac-
tivity or at least sustained activity following PDK1
phosphorylation [6]. Dynamic PKC activation in a cell
has been best illuminated by the use of CKARS by
Alexandra Newton and colleagues [46-49], and similar
analysis of aPKC is likely to shed further light on
aPKC activation.
Figure 1 Schematic of aPKC isoforms and pseudosubstrate inhibitor ZIP: A) The figure shows the protein structure for PKCλ and PKCζ/
PKMζ proteins including alignment of pseudosubstrate regions for both genes and conserved phosphorylation sites. Note that PKMζ is
the only aPKC lacking a regulatory region. B) Shows the alignment of ZIP and scrambled control peptide seuqneces agaonist the position-specific
scoring matrix logo of PKCζ showing some conservation of critical residues [39].
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A priori PKMζ is an attractive candidate for LTP main-
tenance. Its expression is primarily restricted to neurons
[50]. It also lacks pseudosubstrate-dependent inhibition
[38,51]. This potential autonomous activity suggests that
PKMζ is an important player in LTP maintenance.
Francis Crick first proposed the idea that a kinase with
sustained activity can be the molecule responsible for
storage of memory [52] and some evidence was compiled
for this idea before a molecular candidate was found [7].
Two decades of work by Todd Sacktor and his colleagues
establishes PKMζ as a molecular correlate of LTP main-
tenance and memory storage [6]. PKMζ was originally
thought to be a calpain cleavage-derived kinase active
product of the PKCζ protein [53]. This idea, however, was
eventually revised when it was recognized that PKMζ
could originate from a unique mRNA product expressed
in neurons of the brain [38]. This mRNA localizes to
dendritic sites [54] and is translated, forming the mature
PKMζ, following strong synaptic stimulation [55,56].
This PKMζ synthesis occurs in an mTOR-dependent
and ZIP-reversible fashion suggesting a role of PKMζ
in regulating its own synthesis [55]. Strong synaptic
stimulation is also associated with phosphorylation of
PKMζ on two sites and this is regulated by a broad
variety of kinases, all of which have been linked to
early-LTP and LTP consolidation (Figure 2) [55]. The
generation of a pseudosubstrate inhibitor, ZIP (Figure 1B),
suggested that PKMζ is required for the maintenance of
late-LTP [11]. This was important because previous stud-
ies had suggested that a persistently active kinase wasrequired to maintain late-LTP [7,52]. Hence, the structure
of PKMζ, combined with inhibitor data gave strong
evidence that PKMζ might represent the maintenance
mechanism of late-LTP. Subsequent studies demonstrated
that ZIP was capable of reversing a wide variety of
hippocampal- and/or cortical-dependent learning processes
even long after learning was established [57-66]. Eventually,
it was shown that overexpression of PKMζ enhanced even
established memories whereas expression of a dominant
negative PKMζ protein was capable of diminishing such
memories [12]. Hence, it was suggested that PKMζ was
both necessary and sufficient for the maintenance of late-
LTP and learning and memory [6,12,57]. These studies
where paralleled by a range of studies indicating that LTP
occurs during learning and memory in vivo [67] and that
structural changes in dendritic spines accompany both of
these processes [68-71].
How, then, does PKMζ maintain late-LTP and long-
term memory? It has long been recognized that AMPA
receptor trafficking is a critical feature of long-term
memory and LTP [5,72]. In line with these observations,
PKMζ appears to be involved in trafficking of AMPA
receptors, specifically GluA2, to or from the post-
synaptic density [57,73,74]. Like most of the electro-
physiological and in vivo learning paradigm experiments,
some of this evidence was accumulated using the PKMζ
inhibitor ZIP. However, peptides that act as inhibitors
of n-ethlymaleimide sensitive factor (NSF) –dependent
trafficking of AMPA receptors also disrupted AMPA
receptor trafficking events associated with PKMζ-
dependent learning events [74]. Moreover, the effects
of ZIP on removal of GluA2 from the synapse could be
Figure 2 Proposed role of aPKCs in synaptic plasticity: At most CNS synapses, strong synaptic input leads to an activation of PI3K
signaling and PDK1 activation thereby (1) thereby leading to mTORC1 activation. Engagement of the mTORC1 pathway leads to an
increase in translation at or near synaptic sites (2). Because aPKCs mRNAs localize to dendritic and/or synaptic sites, this mTORC1 activation is
capable of stimulating nascent synthesis of aPKCs, especially PKMζ (3). Because PDK1 is also activated, this strong synaptic input is linked to
increased synthesis and phosphorylation of aPKCs. This enhancement of aPKC number and/or activity at synaptic sites is then linked to increased
trafficking of AMPARs to the postsynaptic density (PSD), thereby promoting LTP maintenance.
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moval from synaptic sites [73]. Hence, the consensus
emerged that PKMζ shifts the balance of AMPA recep-
tor trafficking away from removal from the synapse
toward AMPA receptor movement toward the synapse
(Figure 2) [6]. Consequently, inhibition of PKMζ with
ZIP leads to removal of GluA2 from synaptic sites
[73]. The idea has since emerged that LTP involves
insertion of glutamate (AMPA or kainate) receptors
into the synaptic membrane independently of receptor
subtype and the GluA1 C-terminus, which was thought to
be crucial for LTP. This finding suggests that LTP simply
requires a reserve pool of glutamate receptors that are
available to be shifted toward the post-synaptic density
[75]. It remains to be seen if ZIP disrupts the trafficking or
removal of a wide range of ionotropic glutamate receptors
form the synapse.
Hence, the data discussed above points to a model
wherein synaptic stimulation sufficient to lead to LTPcauses an mTOR-dependent synthesis of PKMζ and
phosphorylation of the protein mediated by PDK1 (the
kinase for the T410 site). This synthesis of PKMζ is
associated with an increase in NSF-dependent trafficking
of GluA2 to the synapse and the use of ZIP disrupts the
retention of GluA2 in the synapse [6,57]. Therefore, this
model, which must now be questioned based on data
presented below [34,35], suggests that PKMζ initiates
and maintains late-LTP and learning and memory by
shifting the balance of AMPA receptors toward accumu-
lation at the synapse.
Role of PKMζ in and effects of ZIP on pain
plasticity
As mentioned above, CNS plasticity is well recognized
as a mechanism of pain amplification and this plasticity
is thought to underlie the development of many chronic
pain states [3,15,23,24,76]. However, it has only recently
been suggested that PKMζ might play a role in this
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of Min Zhuo and Bong-Kiun Kaang in 2010 [29]. Using
a nerve injury model in mice, these authors showed that
peripheral nerve injury is accompanied by an early in-
crease in PKMζ expression and a persistent increase in
PKMζ phosphorylation in the ACC. Consistent with a
role for PKMζ in CNS plasticity leading to neuropathic
pain, ZIP infusion into the ACC relieved mechanical
allodynia in these mice and led to a conditioned place
preference suggesting relief of spontaneous pain via an
ACC, PKMζ-related mechanism. Finally, these authors
demonstrated that ZIP exposure to ACC slices prepared
from neuropathic animals led to a decrease in AMPA
receptor-mediated currents, whereas ZIP had no effect
in sham mice. This finding is consistent with the notion
that peripheral nerve injury leads to the insertion of
AMPA receptors in a ZIP-reversible fashion, similarly to
observations in other cortical or hippocampal areas in
learning paradigms [73,74,77]. Somewhat surprisingly, in
this work, there was no effect of ZIP when it was infused
into the spinal cord in neuropathic animals and ZIP
failed to distinguish between AMPA receptor current
densities between neuropathic and sham animals, al-
though it suppressed these currents in both groups.
Hence, at least in the case of neuropathic pain, a ZIP-
reversible form of plasticity in the ACC appears to be a
key feature of this pain state whereas the spinal cord
plays only a minor role [29]. Subsequent studies from
Sandkuhler’s group suggested that ZIP does not reverse
late-LTP at C-fiber synapses in the outer lamina of the
dorsal horn [78]. Hence, there may be fundamental
differences between the effects of ZIP in hippocampus
and cortex vs. this synapse in the dorsal horn. This pos-
sibility and its implications will be discussed below.
These findings in the ACC are further supported by
data from our labs, in collaboration with Frank Porreca.
We found that, in rats, PKMζ phosphorylation is
increased in the rostral ACC (rACC) and rACC infusion
of ZIP leads to a long lasting (at least 3 days, and up to
7 days long) reversal of ongoing neuropathic pain [33].
In contrast to findings in mice, we did not observe any
change in neuropathic allodynia over this same time
course when ZIP was infused into the rACC of rats. This
discrepancy is difficult to rectify but may be due to a
species difference between the neuroanatomical segrega-
tion of tonic aversive and sensory discriminative aspects
of pain insofar as ACC treatments and/or lesions have
reliably shown no effect on tactile thresholds in rats
whereas they demonstrate robust relief of tonic aversive
aspects of pain across multiple models in this species.
On the other hand, several groups have demonstrated
relief of tactile hypersensitivity in mice with ACC
treatments, especially in neuropathic models. In the
spinal cord, we also failed to observe any change inPKMζ protein levels or phosphorylation after peripheral
nerve injury. Moreover, spinal infusion of ZIP failed to
influence mechanical allodynia or spontaneous pain
evoked by spinal nerve ligation (SNL) surgery. On the
other hand, ZIP treatment did lead to a transient rever-
sal of thermal hyperalgesia [33]. Since the presence of
neuropathic allodynia after nerve injury has been shown
to persist even after the ablation of all nociceptive fibers
in mice, this finding, which has now been replicated in
the chronic constriction injury (CCI) model [30],
suggests that this form of allodynia is not dependent on
a ZIP-reversible process in the spinal cord. Thermal
hyperalgesia, on the other hand, appears to be dependent
on a spinally-encoded, ZIP-reversible process [33]. Hence,
a ZIP-reversible form of plasticity contributes to key
features of neuropathic pain and this is positively
correlated with a long-lasting increase in phosphoryl-
ation of PKMζ, but not increased synthesis, in the ACC
of mice and rats.
In contrast to neuropathic pain, a spinal, ZIP-
dependent process appears to be crucial to other types
of chronic pain and this plasticity is, in some cases,
paralleled by changes in PKMζ phosphorylation and
synthesis. We sought out to understand whether PKMζ
might be involved in maintaining a chronic pain state
utilizing models of hyperalgesic priming pioneered by
Jon Levine and colleagues [25-27,79-81]. Hyperalgesic
priming models involve the exposure to an algogen or
an inflammatory mediator followed by a brief period of
hyperalgesia or allodynia. The “primed” animal is then
exposed to a low dose of an inflammatory mediator,
such as prostaglandin E2 (PGE2) which fails to promote
a state of tactile hypersensitivity in naïve animals but in
the primed animal elicits a long-lasting (at least 24 hrs)
state of hypersensitivity. This model, therefore, has the
advantage of a clearly delineated initiation phase
(priming) followed by a period of maintenance with
no outward signs of hypersensitivity until a low dose
inflammatory mediator is given to elicit a state of
hypersensitivity. Building on existing data showing that
interleukin-6 (IL-6) can induce such priming in rats
[80], we demonstrated that this effect can be
reproduced in mice [28,82]. Matching initial injections
of IL-6 into the paw with intrathecal injection of spe-
cific kinase inhibitors demonstrated that initiation
mechanisms in this model are very consistent with
similar studies conducted in hippocampal learning tasks.
Hence, initiation of priming is mTOR-, CaMKIIα- and
classical PKC-dependent. However, a much different pic-
ture emerges when these same inhibitors are utilized dur-
ing the maintenance phase of hyperalgesic priming when
these same doses fail to reverse the exaggerated response
to inflammatory mediator exposure. On the other hand,
ZIP treatment, either during the initiation or maintenance
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sequent exposure to the inflammatory mediator [28].
Consistent with a role for AMPA receptor trafficking in
the persistence of this priming effect, a peptide that
disrupts NSF-dependent AMPA receptor trafficking
[74] mimics the effects of ZIP. This, then, is consistent
with a PKMζ-dependent maintenance mechanism for
hyperalgesic priming. Importantly, this is not a peculiar-
ity of the IL-6 priming model as an identical pharmaco-
logical pattern is produced with plantar incision as the
priming stimulus. The effects are also independent of
the precipitating stimulus as centrally-mediated, mGLuR1/
5-dependent precipitation of exaggerated nocifensive
responses are also ZIP- and AMPA receptor trafficking-
dependent in the maintenance phase [28]. Hence, al-
though hyperalgesic priming has a strong nociceptor
plasticity-dependent component, the spinal cord encodes
an engram for precipitation of a long-lasting hypersensi-
tivity following priming that is ZIP-reversible, suggesting a
potential role for PKMζ. This notion is further supported
by the finding that virally-mediated expression of a
membrane targeted PKCζ, making the protein constitu-
tively active, like PKMζ, recapitulates hyperalgesic prim-
ing behavior without the priming event. Therefore,
similarly to overexpression of PKMζ enhancing learning
and memory, overexpression of a PKMζ mimetic is
sufficient to achieve a long-lasting state of spinally-
mediated pain plasticity [28].
A potential role for PKMζ in spinal pain amplification
is not limited to the hyperalgesic priming model. Two
groups have now demonstrated that ZIP injection into
the spinal cord leads to an inhibition of the 2nd phase
formalin-induced nocifensive behaviors [30,32], even
when ZIP is administered following the cessation of the
1st phase [30]. This is also positively correlated with an
increase in PKMζ phosphorylation [32] and an increase
in total PKMζ levels in the spinal dorsal horn [30].
Paralleling these findings in the formalin test, intraplantar
capsaicin treatment specifically stimulates an increase in
dorsal horn PKMζ levels among aPKCs and ZIP leads to a
reversal of capsaicin-evoked mechanical allodynia [30].
Importantly, these effects are not limited to behavioral
manifestations as ZIP, but not scrambled ZIP, administra-
tion to the spinal cord inhibits formalin-induced action
potential firing of wide dynamic range (WDR) neurons
[32] and capsaicin-evoked mechanical hypersensitivity of
WDR neurons [30]. Finally, ZIP administration to the
spinal cord reverses wholesale inflammation-induced
thermal and mechanical hyperalgesia, albeit transiently,
and likewise decreases spinal c-FOS expression [32].
Importantly, using a model of chronic post ischemic
pain (CPIP) that is initially dependent on afferent dis-
charge but transitions to a centrally-maintained chronic
pain state, Laferriere and colleagues demonstrate thatspinal administration of ZIP during the centrally-
maintained phase of the model leads to a complete and
seemingly permanent reversal of mechanical hypersen-
sitivity [30]. This observation is highly compatible with
findings in the hyperalgesic priming model [28] and
suggests that a centralized chronic pain state, that is no
longer dependent on afferent discharge, is reversible by
a single infusion of ZIP into the spinal cord [28,30].
Regulation of PKMζ phosphorylation and
synthesis
The regulation of aPKC phosphorylation has been the
topic of intensive investigation and it is now well under-
stood that T410 phosphorylation is mediated by PDK1
[83] whereas T560 is an autophosphorylation and/or
mTORC2 site [84] and these sites also appear to be the
key residues for regulation of PKMζ. Synthesis of PKMζ
is regulated by a variety of factors, however, the key step
in this process, for activity-dependent translation, is
stimulation of the mTOR pathway [55], consistent with
a key role for mTOR in the initiation of synaptic plasti-
city [85] (including pain plasticity [28,86]). While these
intracellular mediators are known, extracellular factors
involved in the regulation of PKMζ have been harder to
pin down.
Over the past two years one key factor has emerged,
brain derived neurotrophic factor (BDNF). BDNF is an
important molecule for synaptic plasticity in the CNS
[87-89] and has been linked to diverse processes includ-
ing learning and memory [87-89], addiction [90-92] and
pain plasticity [93-95]. BDNF and PKMζ, based on data
obtained with ZIP, cooperate to govern metaplasticity in
the hippocampus [96]. Moreover, BDNF signaling via its
receptor, trkB, engages a ZIP reversible phosphorylation
of a palmitoylation enzyme called ZDHHC8 involved in
the synaptic localization of post synaptic density protein
95 (PSD95) [97]. In the spinal cord, we have recently
shown that exposure of spinal synaptosomes to BDNF
leads to an increase in nascent synthesis of PKMζ and
PKCλ that is dependent on mTOR activation [98]. BDNF
similarly increases PKMζ phosphorylation at T410. Spinally
applied BDNF promotes hyperalgesic priming that is
reversible by spinal infusion of ZIP suggesting a link to
a functional role of PKMζ and/or PKCλ in BDNF-
induced chronic pain [98]. Interestingly, our findings
with BDNF inhibitors, applied either spinally or system-
ically, indicate that BDNF signaling through trkB plays
an essential role in the maintenance of hyperalgesic
priming. Hence, these findings collectively indicate a
key role for BDNF in not only the initiation of chronic
pain states (as has been shown for inflammatory pain
[99]) but also in the maintenance of such pain states
[98]. They also implicate an active role for BDNF in
regulating PKMζ and/or PKCλ during the maintenance
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peutic strategies wherein a single treatment with BDNF
signaling disrupting agents might be capable of per-
manently reversing a centralized chronic pain state.
Another tyrosine kinase receptor-linked pathway may
play an important role in regulating PKMζ, activation of
nerve growth factor (NGF) signaling via trkA or p75
[100]. In contrast to the studies mentioned above, this
pathway has been implicated in the regulation of excit-
ability of peripheral nervous system (PNS) neurons of
the dorsal root ganglion (DRG). Here it has long been
understood that NGF alters the excitability of adult
DRG neurons but downstream mechanisms involved in
this effect are still under investigation. Zhang et al.,
demonstrated the NGF stimulated an enhanced excit-
ability of DRG neurons that was reversible by ZIP and
PI3K inhibitors. Interestingly, this enhanced excitability
was also blocked by siRNA treatments that decreased
PKMζ but not PKCζ or PKCλ expression, suggesting a
specific role for PKMζ in this effect [100]. Moreover, in-
fusion of recombinant PKMζ recapitulated the effect of
NGF. Hence, NGF appears to regulate DRG excitability
via a PKMζ-dependent process.
Another receptor system crucial for regulation of
PKMζ is the group I metabotropic glutamate receptor
family (mGluR1/5). First, DHPG, an agonist of these
receptors, permits for metaplasticity in a ZIP-dependent
fashion suggesting a role for mGluR1/5 in regulation of
PKMζ [96]. More direct evidence comes from work
done examining the effects of DHPG in the spinal cord.
Activation of spinal mGluR1/5 receptors stimulates
nocifensive behavior and long-lasting mechanical hyper-
sensitivity that has hitherto been largely attributed to
MAPK, specifically ERK, activation [28,86,101-105].
However, spinal activation of mGluR1/5 receptors with
DHPG also stimulates a long lasting increase in total
PKMζ levels [30]. Moreover, DHPG-induced allodynia is
completely reversed by spinal administration of ZIP [30]
suggesting that mGluR1/5-mediated mechanical hyper-
sensitivity is maintained by a persistent increase in
PKMζ levels. Hence, in the pain pathway, as well as in
crucial learning and memory circuits, BDNF/trkB [98]
and mGluR1/5 [28,30] appear to act as key regulators of
PKMζ synthesis, phosphorylation and their downstream
physiological consequences.
ZIP as a specific inhibitor of PKMζ
As described above, investigators examining the poten-
tial role of PKMζ in synaptic plasticity and accompany-
ing behavioral manifestations of such plasticity have
relied heavily on ZIP as a tool to interrogate the func-
tion of PKMζ (Figure 1B). Hence, this area is highly
dependent on the specificity of ZIP as a tool to inhibit
PKMζ. This specificity has recently been called intoquestion on several fronts [106,107]. First, an investiga-
tion of PKMζ expressed in a heterologous systems or
examining native activity in brain slices found that ZIP
failed to block kinase activity of the enzyme [106],
however, a subsequent report disputed some of the
conclusions posited by Wu-Zhang and colleagues [108].
Furthermore, a scrambled peptide is routinely used as
negative control. However, assessment of binding interface
determined by positional scanning of oriented peptide
libraries indicates that the control peptide may bind to
aPKCs, including PKMζ (Figure 1B). Indeed, recent
reports [34,35] and our unpublished observations con-
firm the lack of specificity and isoform selectivity
in vitro. The basis of its lack of PKMζ inhibition in vivo
remains unknown. Chelerythrine, a benzophenanthridine
alkaloid which is reported to inhibit PKMζ inhibition
in vivo [53] fails to inhibit aPKC in vitro [106,109]. While
the controversy over the activity of ZIP against kinase
activity in cells (versus in vitro assays) continues [106,108],
two recent papers have raised the specter that ZIP
possesses targets other than PKMζ and that these targets
may, in fact, represent the mechanism of action of ZIP
for disruption of late-LTP and long-term memory [34,35].
The derivation of ZIP sequence from the autoinhibitory
pseudosubstrate peptide sequence of PKCζ ostensibly
confers its specificity for PKCζ and PKMζ. The
pseudosubstrate sequence of PKCλ is identical to ZIP
(Figure 1A). The PKC substrate peptide often used in
in vitro kinase assay also shares substantial identity.
Finally, ZIP inhibits PKCλ in in vitro kinase assays
[35]. The most definitive proof of “off-target” effect
however is the ability of ZIP to affect memory storage
in PKMζ knockout mouse [34,35]. Notwithstanding,
these studies suggest that ZIP functions in erasing
memory storage by perturbing the biological activity
of an alternative target.
Functional redundancy and speculations on
alternative targets of ZIP
While genetic ablation of PKMζ clearly establishes that
it is not necessary for LTP maintenance and memory
storage [34,35], these studies do not rule out PKMζ
function in memory. Fundamental processes in biology,
such as maintenance mechanisms of LTP, most likely
involve functional redundancy of signaling pathways
and components. A key cellular function of aPKCs is in
the regulation of cell polarity. Here, as part of the Par
complex, aPKCs establishes asymmetry within a cell, in-
cluding during the first cell division in C. elegans
embryo. Functional analogy between polarity and mem-
ory roles of aPKCs have been indicated [57]. A recent
RNAi screen in C. elegans demonstrates that functional
redundancy of the signaling network masks the func-
tion of individual polarity components [110]. Single
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tion of molecules in complex physiological processes. One
particularly striking example is the Tyro3, Axl and Mer
family of receptor tyrosine kinases. The genetic ablation of
all three members was necessary to fully reveal their bio-
logical function [111]. A similar redundancy between PKC
isoforms is conceivable.
Another possibility is that the ZIP-mediated effect on
LTP maintenance in wild-type and PKM/PKCζ knockout
mice occurs not because of its ability to target PKMζ,
but its efficacy in targeting an unidentified protein. This
elusive protein is perhaps necessary and sufficient for
LTP maintenance. So what may be the molecule that
accounts for redundancy or is the elusive, true memory
storage molecule? The aPKC isoform – PKCλ, is expressed
in neurons, including in the hippocampus, cortex, and
amygdala ([112] and our unpublished data) and is
inhibited by ZIP with the same kinetics as PKMζ ([35]
and our unpublished data). It has also been reported
that overexpression of PKMζ enhances, while expres-
sion of kinase-inactive PKMζ functions as dominant
negative in LTP maintenance [12]. Because the PKCλ
kinase domain shares 86% identity at the amino acid
level with PKMζ, it is likely that many of the molecular
targets will be shared between these isoforms, particu-
larly during overexpression. Therefore, it is not outside
the realm of possibility that genetic deletion of PKM/
PKCζ, as has recently been done [34,35], reveals a func-
tionally redundant and crucial role of PKCλ in mainten-
ance of late-LTP and long term memory storage.
Conditional knockout of PKCλ (interestingly, conven-
tional knockout of PKCλ is lethal [113,114], while many
other PKCs are dispensable for life) or isoform-selective
inhibitors merit testing for effects on memory storage
and chronic pain. A systematic analysis of ZIP targets,
based on predicted homology or unbiased screens,
combined with genetic knockouts may yet reveal the
secret of the elusive memory molecule.
Deciphering the effects of ZIP and the role of
PKMζ in pain plasticity
There are several possible ways to interpret the studies
mentioned above demonstrating a lack of specificity of
ZIP for PKMζ in late-LTP maintenance and long-term
memory storage in relation to their relevance for studies
examining pain plasticity. Below we will consider some
of those possible interpretations and their ramifications
for understanding the role of aPKCs in pain plasticity.
1) It is possible that PKMζ is the sole target for ZIP in
the pain pathway and that studies examining
hippocampal and cortical effects of ZIP will
ultimately not be paralleled by spinal ZIP application
studies (Figure 3A1 and 3A2). In many ways thisresult would be very exciting for the development of
therapeutics because it would suggest that small
molecule inhibitors of PKMζ could be developed for
inhibition or reversal of pathological pain plasticity
that would not have an influence, necessarily, on
learning and memory. While this possibility may
sound improbable based on the literature discussed
above, there are some important points to consider.
First, as mentioned above, there is already some
evidence that ZIP fails to reverse late-LTP at
synapses between C-fibers and second order outer
lamina neurons [78]. This occurs despite the fact
that ZIP has clear and robust effects in several pain
models [28-30,32,33,98], including a complete
reversal of a centralized pain state with a single dose
in hyperalgesic priming and CPIP models [28,30,98].
Hence, ZIP may have an effect on physiological
process that are distinct from LTP in the spinal cord
but that are nevertheless crucial for pain plasticity.
In that regard, it is important to note that ZIP
reverses hyperalgesic priming even when priming-
induced allodynia has completely resolved [28,98].
While the pharmacology of this event is consistent
with the pharmacology of early- vs. late-LTP, the
mere fact that the allodynia resolves questions the
relevance of LTP in this model, especially at afferent /
second order neuron synapses.
2) Another possibility is that functional redundancy of
aPKCs is a key feature of pain plasticity in a similar
fashion to what might well be observed in learning
and memory processes (Figure 3B). This is, from an
evolutionary perspective, a tantalizing possibility
especially considering the important teaching
function that the nociceptive system possesses for
the survival of complex organisms [115]. As
mentioned above, the fact that ZIP has inhibitory
activity at PKCλ, combined with the demonstrated
activity of ZIP in PKM/PKCζ knockout mice [34,35],
point to the clear need for experiments aimed at
assessing a potential role for PKCλ as an important
molecule for synaptic plasticity in multiple systems
and pathways. In this regard, it should not be
forgotten that overexpression of aPKCs in memory
[12] or pain circuits [28] is sufficient to enhance
memory or induce a chronic pain state, respectively.
Moreover, we have shown that PKMζ and PKCλ are
regulated in a similar fashion at spinal synapses [98].
We are unaware of other scenarios where a class of
enzyme is, on the one hand, sufficient for an effect
whereas it is, on the other hand, not necessary for
the same effect. Based on these factors, we favor the
functional redundancy hypothesis as the most
parsimonious, albeit untested, solution to this
problem.
Figure 3 Three hypotheses regarding the role of aPKCs in pain plasticity taking into account recent findings on PKMζ knockout mice:
A1 and A2) One possibility is that while cortical and hippocampal late-LTP is dependent on aPKC function through trafficking of AMPA
receptors (AMPAR) this mechanism is not shared in the dorsal horn. In the dorsal horn PKMζ might be necessary and sufficient for certain
forms of pain plasticity but this is not functionally linked to LTP or AMPAR trafficking and therefore involves a novel, undiscovered mechanism.
Another possibility (B) is that at all CNS synapses aPKCs can serve a functionally redundant role and the absence of PKMζ fails to lead to a strong
phenotype because PKCλ, which is also ZIP-sensitive, can functionally replace PKMζ in its absence. C) A final possibility is that ZIP targets a totally
distinct mechanism to induce neuronal plasticity, however, such a mechanism is likely stimulated by NGF/p75-, BDNF/trkB- and mGluR1/5-
dependent mechanisms that may also, in some cases, be linked to AMPAR trafficking as an endpoint signaling output of the ZIP-sensitive target.
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action that is completely unrelated to aPKC function
(Figure 3C). If this is true, it is interesting to
consider that a wide variety of other kinases have
already been ruled out due to extensive
investigations of maintenance mechanisms of late-
LTP, memory storage and chronic pain. It is highly
likely that such a mechanism would need to also
involve the trafficking of AMPA receptors (or at least
a reserve pool of ionotropic glutamate receptors
[75]) because several previous studies have linked
ZIP and PKMζ effects to this process [28,73,74]. It is
also probable that such a mechanism should also be
regulated by mGluR1/5 [30] and BDNF/trkB
signaling [98] (and likely NGF signaling as well
[100]) since the physiology of these pathways hasbeen linked to ZIP reversible processes. Having said
that, it is still likely that the most judicious path
forward in this regard is the undertaking of true
unbiased screens to determine potential molecular
partners of ZIP action outside of the aPKC family
of kinases.
Concluding remarks
The recent introduction of PKMζ into the pantheon of
pain targets has led to new insights into how pain
becomes chronic while also unveiling new mysteries
of pain physiology (e.g. clear differences in plasticity
mechanisms between ongoing neuropathic and centralized
chronic pain states). New studies demonstrating a lack of
specificity of the central tool in these experiments, ZIP,
have, in some ways, turned this area on its head; however,
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area of work needs. We propose that this field is now ripe
for discovery and the development of hitherto unimagined
tools that will dramatically enhance our understanding of
the role, or lack thereof, for aPKCs in fundamental neuro-
biological processes like pain plasticity. We look forward
to exciting discoveries in this now completely wide-open
area of work in the coming years.
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